AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vakulenko, S.
Right arrow Articles by Golemi, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vakulenko, S.
Right arrow Articles by Golemi, D.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2002, p. 646-653, Vol. 46, No. 3
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.3.646-653.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Mutant TEM ß-Lactamase Producing Resistance to Ceftazidime, Ampicillins, and ß-Lactamase Inhibitors

Sergei Vakulenko1,2* and Dasantila Golemi3

Departments of Biochemistry and Molecular Biology,1 Medicine, Wayne State University, Detroit, Michigan 48201,2 Department of Chemistry, Wayne State University, Detroit, Michigan 482023

Received 17 May 2001/ Returned for modification 23 September 2001/ Accepted 23 November 2001

A derivative of the TEM-1 ß-lactamase producing clinically significant levels of resistance to ceftazidime and ß-lactamase inhibitors in the presence of penicillins was generated following five rounds of DNA shuffling and selection. This complex mutant enzyme contained three amino acid substitutions including those of residues 104 and 276 that are known to produce extended-spectrum resistance and, correspondingly, resistance to ß-lactamase inhibitors. Although the Glu104Lys substitution by itself produced low levels of ceftazidime resistance, additional amino acid replacements in the enzyme with the triple mutation resulted in further enhancement of resistance to ceftazidime. Kinetic studies of the purified ß-lactamase enzyme with the triple mutation indicated enhancement of the catalytic efficiency for turnover (kcat/Km) of ceftazidime. The increases in the Ki values of both clavulanic acid and tazobactam for the enzyme with the triple mutation were consistent with the observed bacterial resistance to the reversibility of ß-lactam resistance with these inhibitors.

* Corresponding author. Mailing address: Department of Chemistry, Wayne State University, 5101 Cass Ave., Room 330, Detroit, MI 48202. Phone: (313) 577-3073. Fax: (313) 577-8822. E-mail: svakulen{at}med.wayne.edu.

Antimicrobial Agents and Chemotherapy, March 2002, p. 646-653, Vol. 46, No. 3
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.3.646-653.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2002 by the American Society for Microbiology. All rights reserved.